Cadence
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
mm
By Sugata Biswas In Communications

Cultural Biases and Respondent Tendencies in International Market Research

The reality is that respondents take and answer surveys differently¬ based off their geography and culture, irrespective of the survey…
Read More
Communications

General Data Protection Regulation Compliance: Securing Data to Create Value

By Sugata Biswas | Communications
Communications

COVID-19 Background and Insights: Epidemiology

By Zachary Moore | Communications
Communications

COVID-19 Background and Insights: Virology

By Zachary Moore | Communications
Communications

Top 5 Ways to Make Your Virtual Meeting a Success

By Sugata Biswas | Communications
Communications

Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business

By Sugata Biswas | Communications

For the 3rd Time, Women-Owned Cadence Communications & Research Appears on the Inc. 5000, Ranking No. 3160 With Three-Year Revenue Growth of 116%

Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies

ALL CADENCE INSIGHTS

All
Market Access
Market Research
Medical Communications
Oncology Updates
Methodologies
Communications

Cultural Biases and Respondent Tendencies in International Market Research

Theory of Mind and the Top Five Things You Can do to Avoid Moderator-Likeability Bias

General Data Protection Regulation Compliance: Securing Data to Create Value

COVID-19 Background and Insights: Epidemiology

COVID-19 Background and Insights: Virology

Top 5 Ways to Make Your Virtual Meeting a Success

Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business

Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies

White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer

Client Testimonials

Clinical Case Forum

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

Take a Look Into Our Market Access Work

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

Act NOW!

Tips on Cultivating Vision in your Organization

Reflections on the Legacy of Dick Fordyce

Starbucks, Pumpkin Spice Latte and Why Medical Myths Persist in the Age of Information

The Cadence Concierge Experience

Meeting Planning Processes 101’s

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

What Does it Mean for a Vendor to be of Service?

Leveraging Innovation Centers to Re-prime the Development Pump!

What are the biggest concerns manufacturers have about the Sunshine Act?

Will the Sunshine Act eliminate bias from the US healthcare system?

Mixology…Blending Methodologies for Today’s Challenges

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL

Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML

Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy

Founder’s Blog: Why You Should Give a Damn about Your Vendor’s Culture

Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer

Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer

Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors

Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer

Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC

What can the Pharmaceutical industry do to re-prime its development pump?

Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution

How do we mix qualitative insight with quantitative research?

Why Cadence Achieved Status as One of Inc.’s Fastest-Growing Private Companies for Second Year in a Row!

The Forward March of Regress

What will be the impact of the ACA on cancer treatment?

Advice from Founder of Cadence Research, One of Inc.’s Fastest-Growing Private Companies in 2012

Third time on the Inc. 5000, Ranking No. 3160 Learn More

Terms of Use | Privacy Policy

TRUSTe
"We use cookies to give you the best possible experience on our website. To learn more about cookies and how we use them please see our cookie policy here. See more information on changing cookie preferences here. Please be aware the site may not function properly without cookies. [ ] I consent.”
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT